AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?

Core Insights - The article compares two companies in the Medical - Drugs sector: Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX), focusing on which stock may be undervalued for investors [1][3] Valuation Metrics - AMLX has a forward P/E ratio of 10.06, significantly lower than NBIX's forward P/E of 29.42, indicating that AMLX may be undervalued [2] - The PEG ratio for AMLX is 0.15, while NBIX has a PEG ratio of 0.75, suggesting that AMLX has a better growth outlook relative to its valuation [2] - AMLX's P/B ratio is 2.52 compared to NBIX's P/B of 6.97, further indicating that AMLX is more attractively valued [2] Investment Ratings - AMLX currently holds a Zacks Rank of 2 (Buy), while NBIX has a Zacks Rank of 3 (Hold), reflecting a stronger earnings outlook for AMLX [1] - Based on the analysis of valuation metrics and estimate revisions, AMLX is deemed the superior option for value investors at this time [3]